Polyrizon completes contracts for five U.S. sites in NASARIX first-in-human seasonal allergic rhinitis trial
PLRZ•Trial site contracting completed
Polyrizon completed contracts for all five U.S. sites for a first-in-human trial of NASARIX Allergy Blocker in seasonal allergic rhinitis.
No clinical results have been presented; efficacy and safety data are expected in the future once enrollment and follow-up are completed.
The study aims to show symptom relief versus saline control, with acceptable tolerability, under real-world seasonal allergen exposure.
Up to 120 patients are planned, with recruitment timed to allergy seasons, moving the program from setup into execution.
